COVID-19 Therapeutics Table


  mAbs Oral Antivirals PrEP
Products Bebtelovimab
(Eli Lilly)
Molnupiravir
(Merck)
Paxlovid
(Pfizer)
Tixagevimab/Cilgavimab
(EVUSHELD)
Authorized Use(s) Treatment of mild to moderate symptoms Treatment of mild to moderate symptoms Treatment of mild to moderate symptoms Pre-exposure prevention for immunocompromised individuals
Age Eligibility Ages 12 years and older Ages 18 and older Ages 12 years and older Ages 12 years and older
Weight Eligibility 88 pounds or more No weight requirement 88 pounds or more 88 pounds or more
Other Criteria for Treatment Test Positive for SARS-CoV-2

Be within 7 days of the start of symptoms

Not be hospitalized

Not require oxygen and/or respiratory support
Test Positive for SARS-CoV-2

Be within 5 days of the start of symptoms

Not be hospitalized
Test Positive for SARS-CoV-2

Be within 5 days of the start of symptoms

Not be hospitalized
Not currently infected with SARS-CoV-2

Have not had a known recent exposure to an infected individual with SARS-CoV-2
Other Criteria for Prevention       Must have moderate to severe immune compromise due to a medical condition diagnosed by a health care provider
Letter of Authorization Bebtelovimab Letter of Authorization (EUA) Molnupiravir EUA Letter of Authorization Paxlovid EUA Letter of Authorization Evusheld EUA Letter of Authorization (EUA)
EUA Fact Sheet Bebtelovimab Provider Fact Sheet Molnupiravir Provider Fact Sheet Paxlovid Provider Fact Sheet Evusheld Provider Fact Sheet